Published in Blood on October 20, 2005
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol (2010) 4.03
Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal (2011) 3.31
Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med (2011) 3.11
Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells (2009) 3.01
Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med (2009) 2.83
Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng (2010) 2.66
Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant (2010) 2.50
Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One (2010) 2.38
Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol (2012) 2.36
Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells (2010) 2.25
Immunobiology of mesenchymal stem cells. Cell Death Differ (2013) 2.18
Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol (2010) 2.12
Stem cell paracrine actions and tissue regeneration. Regen Med (2010) 1.99
Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol (2009) 1.88
Clinical applications of mesenchymal stem cells. J Hematol Oncol (2012) 1.86
Dual origin of mesenchymal stem cells contributing to organ growth and repair. Proc Natl Acad Sci U S A (2011) 1.77
Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol (2011) 1.73
Regulation of ligands for the activating receptor NKG2D. Immunology (2007) 1.55
Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol (2012) 1.50
Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells (2008) 1.46
Immunomodulatory properties of stem cells from human exfoliated deciduous teeth. Stem Cell Res Ther (2010) 1.43
Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med (2009) 1.42
Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther (2007) 1.35
Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med (2012) 1.32
Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunol Cell Biol (2013) 1.29
Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy. World J Stem Cells (2014) 1.29
Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells (2008) 1.28
The life and fate of mesenchymal stem cells. Front Immunol (2014) 1.27
Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood (2012) 1.27
Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev (2013) 1.26
Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol (2009) 1.25
Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells. J Biomed Sci (2011) 1.20
Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. J Cell Mol Med (2011) 1.18
Role of mesenchymal stromal cells in solid organ transplantation. Transplant Rev (Orlando) (2008) 1.17
The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol (2011) 1.16
Therapeutic potential of mesenchymal stem cells in regenerative medicine. Stem Cells Int (2013) 1.14
Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells (2014) 1.14
Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy. Curr Pharm Des (2013) 1.13
Mesenchymal stromal cells: a new tool against graft-versus-host disease? Biol Blood Marrow Transplant (2011) 1.11
A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions. Cell Mol Immunol (2010) 1.10
Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation. Int J Mol Med (2014) 1.10
Mesenchymal stem cell-based therapy. Mol Pharm (2012) 1.09
Flk-1+ mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6. Clin Exp Immunol (2009) 1.09
Comparative study of immune regulatory properties of stem cells derived from different tissues. Stem Cells Dev (2013) 1.08
Macrophages in injured skeletal muscle: a perpetuum mobile causing and limiting fibrosis, prompting or restricting resolution and regeneration. Front Immunol (2011) 1.08
Mesenchymal stem cells at the intersection of cell and gene therapy. Expert Opin Biol Ther (2010) 1.07
Mesenchymal stromal cells: a key player in 'innate tolerance'? Immunology (2012) 1.07
Mesenchymal stem cells as all-round supporters in a normal and neoplastic microenvironment. Cell Commun Signal (2012) 1.06
Interplay between mesenchymal stem cells and lymphocytes: implications for immunotherapy and tissue regeneration. J Dent Res (2012) 1.05
Human mesenchymal stem cells - current trends and future prospective. Biosci Rep (2015) 1.04
Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis (2016) 1.03
Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation. PLoS One (2011) 1.02
The immunomodulatory and neuroprotective effects of mesenchymal stem cells (MSCs) in experimental autoimmune encephalomyelitis (EAE): a model of multiple sclerosis (MS). Int J Mol Sci (2012) 1.02
Mesenchymal stem cells as a potent cell source for articular cartilage regeneration. World J Stem Cells (2014) 1.01
Mesenchymal stem cells: from biology to clinical use. Blood Transfus (2007) 1.00
Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo. PLoS One (2014) 1.00
Mesenchymal stem cells: biology and clinical potential in type 1 diabetes therapy. J Cell Mol Med (2008) 0.99
Clinical applications of mesenchymal stem cells in chronic diseases. Stem Cells Int (2014) 0.98
An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease. Haematologica (2011) 0.97
Clinical Application of Mesenchymal Stem Cells in the Treatment and Prevention of Graft-versus-Host Disease. Adv Hematol (2011) 0.97
Adverse fibrosis in the aging heart depends on signaling between myeloid and mesenchymal cells; role of inflammatory fibroblasts. J Mol Cell Cardiol (2013) 0.96
Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer (2013) 0.96
Prospective isolation of murine and human bone marrow mesenchymal stem cells based on surface markers. Stem Cells Int (2013) 0.96
Paracrine molecules of mesenchymal stem cells for hematopoietic stem cell niche. Bone Marrow Res (2011) 0.96
Immunomodulative efficacy of bone marrow-derived mesenchymal stem cells cultured in human platelet lysate. J Clin Immunol (2011) 0.96
MSC microvesicles for the treatment of lung disease: a new paradigm for cell-free therapy. Antioxid Redox Signal (2014) 0.95
Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis. Stem Cells Dev (2011) 0.95
Strategies to rescue mesenchymal stem cells (MSCs) and dental pulp stem cells (DPSCs) from NK cell mediated cytotoxicity. PLoS One (2010) 0.95
Mesenchymal stem cell therapy for liver fibrosis. Korean J Intern Med (2015) 0.95
Mesenchymal Stem Cells: Rising Concerns over Their Application in Treatment of Type One Diabetes Mellitus. J Diabetes Res (2015) 0.95
Enhanced mesenchymal stromal cell recruitment via natural killer cells by incorporation of inflammatory signals in biomaterials. J R Soc Interface (2011) 0.95
Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells. Anesthesiology (2014) 0.94
Concise review: immunomodulatory properties of mesenchymal stem cells in cellular transplantation: update, controversies, and unknowns. Stem Cells Transl Med (2012) 0.94
The Oncogenic Potential of Mesenchymal Stem Cells in the Treatment of Cancer: Directions for Future Research. Curr Immunol Rev (2010) 0.93
Cytokine secretion profiling of human mesenchymal stem cells by antibody array. Int J Stem Cells (2009) 0.93
Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs. Exp Hematol (2010) 0.93
Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: what do we know so far? Biomed Res Int (2014) 0.92
Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions. Biol Blood Marrow Transplant (2009) 0.92
Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease. Clin Exp Immunol (2013) 0.92
IFN-γ stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro. Stem Cells Dev (2013) 0.92
Mesenchymal stem cell-derived hepatocytes for functional liver replacement. Front Immunol (2012) 0.91
Mesenchymal stem cell therapy in the treatment of acute and chronic graft versus host disease. Front Oncol (2011) 0.91
Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T-cell proliferation and B-cell survival. Haematologica (2010) 0.91
The role of immunosuppression of mesenchymal stem cells in tissue repair and tumor growth. Cell Biosci (2012) 0.91
Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells. Curr Immunol Rev (2009) 0.91
Stem cells and regenerative medicine: accomplishments to date and future promise. Ther Deliv (2010) 0.90
Bone marrow-derived stem cells ameliorate hepatic fibrosis by down-regulating interleukin-17. Cell Biosci (2013) 0.90
Mesenchymal stromal cells in transplantation rejection and tolerance. Cold Spring Harb Perspect Med (2013) 0.90
Mesenchymal stem cells, not conditioned medium, contribute to kidney repair after ischemia-reperfusion injury. Stem Cell Res Ther (2014) 0.90
The Dark Side of the Force - Constraints and Complications of Cell Therapies for Stroke. Front Neurol (2015) 0.89
Modulation of human mesenchymal stem cell immunogenicity through forced expression of human cytomegalovirus us proteins. PLoS One (2012) 0.89
Mesenchymal stem-cell immunosuppressive capabilities: therapeutic implications in islet transplantation. Transplantation (2010) 0.89
Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of human mesenchymal stem cell transplants. PLoS One (2011) 0.88
Adenoviral virotherapy for malignant brain tumors. Expert Opin Biol Ther (2009) 0.88
Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity. BMC Cancer (2010) 0.88
Immunological properties of embryonic and adult stem cells. World J Stem Cells (2010) 0.87
Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors. Bone (2014) 0.87
Production of reactive oxygen species by multipotent stromal cells/mesenchymal stem cells upon exposure to fas ligand. Cell Transplant (2012) 0.87
Mesenchymal stem cell therapy and acute graft-versus-host disease: a review. Hum Cell (2014) 0.87
Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Res Ther (2016) 0.86
Mesenchymal stem cells in health and disease. Nat Rev Immunol (2008) 11.14
Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med (2002) 4.32
Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med (2003) 3.52
Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood (2007) 3.38
CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol (2007) 2.97
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A (2003) 2.71
Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A (2004) 2.66
Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res (2012) 2.54
Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A (2003) 2.51
Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol (2007) 2.50
Immunoregulatory function of mesenchymal stem cells. Eur J Immunol (2006) 2.47
NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood (2005) 2.31
The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol (2003) 2.29
CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A (2004) 2.23
What is a natural killer cell? Nat Immunol (2002) 2.11
NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol (2002) 2.02
CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood (2003) 1.99
Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A (2004) 1.95
A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood (2012) 1.92
Surface NK receptors and their ligands on tumor cells. Semin Immunol (2006) 1.92
Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res (2004) 1.87
Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol (2007) 1.86
Cellular ligands of activating NK receptors. Trends Immunol (2005) 1.84
The three-dimensional structure of the human NK cell receptor NKp44, a triggering partner in natural cytotoxicity. Structure (2003) 1.82
Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood (2011) 1.78
Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A (2010) 1.74
Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev (2006) 1.71
A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood (2010) 1.67
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer (2008) 1.66
The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol (2003) 1.60
Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood (2005) 1.57
Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood (2010) 1.56
Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood (2011) 1.56
The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur J Immunol (2003) 1.55
Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. Eur J Immunol (2004) 1.53
The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol (2004) 1.50
Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. Blood (2002) 1.49
Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol Rev (2008) 1.47
NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol (2009) 1.46
Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol (2005) 1.42
Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells (2008) 1.42
The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood (2006) 1.41
Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci U S A (2002) 1.40
Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol (2009) 1.37
Regulatory role of NKp44, NKp46, DNAM-1 and NKG2D receptors in the interaction between NK cells and trophoblast cells. Evidence for divergent functional profiles of decidual versus peripheral NK cells. Int Immunol (2008) 1.36
Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol (2005) 1.35
IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol (2003) 1.35
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.34
Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression. Proc Natl Acad Sci U S A (2010) 1.30
The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc Natl Acad Sci U S A (2010) 1.28
HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proc Natl Acad Sci U S A (2003) 1.27
The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. Blood (2005) 1.26
Structural basis for a major histocompatibility complex class Ib-restricted T cell response. Nat Immunol (2006) 1.23
Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood (2008) 1.22
Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. Blood (2005) 1.22
Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood (2011) 1.22
Human NK cells directly recognize Mycobacterium bovis via TLR2 and acquire the ability to kill monocyte-derived DC. Int Immunol (2008) 1.20
Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. Eur J Immunol (2011) 1.19
Origin, phenotype and function of human natural killer cells in pregnancy. Trends Immunol (2011) 1.18
Cellular and molecular interactions of mesenchymal stem cells in innate immunity. Immunol Cell Biol (2012) 1.16
The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. J Immunol (2005) 1.15
Evidence that the KIR2DS5 gene codes for a surface receptor triggering natural killer cell function. Eur J Immunol (2008) 1.15
Analysis of natural killer cells isolated from human decidua: Evidence that 2B4 (CD244) functions as an inhibitory receptor and blocks NK-cell function. Blood (2006) 1.14
Human natural killer cells: their origin, receptors and function. Eur J Immunol (2002) 1.13
A single amino acid change, A91V, leads to conformational changes that can impair processing to the active form of perforin. Blood (2005) 1.12
Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol Lett (2005) 1.12
Human cytomegalovirus infection promotes rapid maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted with NKG2C-/- umbilical cord blood. J Immunol (2014) 1.12
IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol (2005) 1.11
Multidirectional interactions are bridging human NK cells with plasmacytoid and monocyte-derived dendritic cells during innate immune responses. Blood (2006) 1.11
PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol (2005) 1.11
Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol (2013) 1.10
CD34+ hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc Natl Acad Sci U S A (2011) 1.09
NK-CTLs, a novel HLA-E-restricted T-cell subset. Trends Immunol (2003) 1.09
Selective cross-talk among natural cytotoxicity receptors in human natural killer cells. Eur J Immunol (2003) 1.08